Search PubMed⌕ Search

Biomedical subjects

T Roth

Publications and source records attributed to T Roth.

At least 91 records · Page 5Linked to original sources
PubMed1997

Alerting effects of methylphenidate under basal and sleep-deprived conditions.

Six men and 3 women on each of 4 days received 10 mg of methylphenidate or placebo (2 times a day) at 0800 and 1200 after 8 hr or 0 hr of sleep. Sleep latency was measured by the Multiple Sleep Latency Test (MSLT) at 0930, 1130, 1330, 1530, and 1730. Participants also completed divided-attention and auditory vigilance tasks at 1000 and 1400 and the Profile of Mood States (POMS) and the Addiction Research Center Inventory (ARCI) after the 0930 and 1330 latency tests. The drug increased mean latency on the MSLT in both sleep conditions. Performance only showed drug effects after prior sleep deprivation. On the POMS, the drug increased Vigor and reduced Fatigue and Depression scale scores, primarily after sleep deprivation. The drug increased the ARCI Amphetamine and Morphine-Benzedrine scores only in the basal state. The ARCI Pentobarbital score was increased by sleep deprivation and decreased by the drug.

Adult↗
PubMed1997

Polymicrobial brain abscess in a patient infected with human immunodeficiency virus.

Although intracranial mass lesions that occur as a result of infection have commonly been reported in patients infected with human immunodeficiency virus, polymicrobial pyogenic brain abscess has not been described in this setting. We report the first case of a patient with a polymicrobial brain abscess involving Streptococcus bovis, Fusobacterium necrophorum, Peptostreptococcus, and group G Streptococcus, and we review the relevant world literature.

AIDS-Related Opportunistic Infections↗
PubMed1997

The alerting effects of short and long naps in narcoleptic, sleep deprived, and alert individuals.

Eleven narcoleptic patients and 22 age- and gender-matched normal controls participated in a study to determine the alerting effects of differing nap lengths. All narcoleptic patients had been previously diagnosed [mean sleep latency on the multiple sleep latency test (MSLT) < or = 5 minutes with two or more sleep-onset rapid eye movement periods (SOREMPs)]. Healthy, normal subjects with a mean sleep latency on the screening MSLT > or = 8 minutes were randomly assigned to one of two groups (i.e. sleep-deprived and alert). All subjects completed two experimental night and days with at least 5 days between sessions. On the evening prior to each experimental day, narcoleptic and alert subjects spent 8 hours in bed and sleep-deprived subjects spent 0 hours in bed. The following day, all subjects underwent one of two napping conditions, 15 or 120 minutes in bed. Both naps were terminated at noon. Every subject underwent both conditions and the order of conditions was counterbalanced. From 1215 to 1355 hours all subjects underwent a modified MSLT. At 1500 hours, the subjects had a 1-hour nap. The results showed that the 120-minute nap condition was more beneficial than the 15-minute nap. Narcoleptic and sleep deprived subjects were shown to have comparable levels of sleepiness on the modified MSLT. However, a differential response pattern on their latency to sleep was noted on the 1-hour nap. Sleep-deprived subjects were shown to be differentially more alert following a 120-minute nap opportunity. In contrast, for narcoleptic patients the beneficial effects of the nap were lost when tested 3 hours later. These results show that narcoleptic patients benefit from a longer nap but that these benefits are short-lived.

Adult↗
PubMed1997

Effects of diagnosis on treatment recommendations in chronic insomnia--a report from the APA/NIMH DSM-IV field trial.

The objective of this study was to determine whether sleep specialists and nonspecialists recommend different treatments for different insomnia diagnoses according to two different diagnostic classifications. Two hundred sixteen patients with chronic insomnia at five sites were each interviewed by two clinicians: one sleep specialist and one nonsleep specialist. All interviewers indicated diagnoses using the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV); sleep specialists also indicated diagnoses according to the International Classification for Sleep Disorders (ICSD). Interviewers then indicated how strongly they would recommend each item in a standard list of treatment and diagnostic interventions for each patient. We examined differences in treatment recommendations among the six most common DSM-IV diagnoses assigned by sleep specialists at different sites (n = 192), among the six most common ICSD diagnoses assigned by sleep specialists at different sites (n = 153), and among the six most common DSM-IV diagnoses assigned by nonspecialists at different sites (n = 186). In each analysis, specific treatment and polysomnography recommendations differed significantly for different diagnoses, using either DSM-IV or ICSD criteria. Conversely, different diagnoses were associated with different rank orderings of specific treatment and diagnostic recommendations. Sleep specialist and nonspecialist interviewers each distinguished treatment recommendations among different diagnoses, but in general, nonspecialists more strongly recommended medications and relaxation treatments. Significant site-related differences in treatment recommendations also emerged. Differences in treatment recommendations support the distinction between different DSM-IV and ICSD diagnoses, although they do not provide formal validation. Site-related differences suggest a lack of consensus in how these disorders are conceptualized and treated.

Adolescent↗
PubMed1997

Minimal rebound insomnia after treatment with 10-mg zolpidem.

This study examined rebound insomnia after discontinuation of chronic use of zolpidem (10 mg), a short elimination half-life imidazopyridine. The zolpidem group was bracketed by a placebo group and a positive control group taking 0.5 mg of triazolam (twice the recommended dose), which is known to produce rebound insomnia. Ninety-nine patients with sleep complaints that were polysomnographically documented participated in the study. After randomization, patients completed a 2-night, single-blind, placebo baseline period, a 28-night double-blind treatment phase, and a 3-night, single-blind, placebo substitution period. Polysomnographic and subjective sleep variables indicated a lack of rebound insomnia for the zolpidem group. The positive triazolam control group had rebound insomnia only on the first discontinuation night. There was no significant correlation between rebound insomnia and the level of initial insomnia, the degree of response to treatment in week 4, or the amount of tolerance that developed during drug use. During the 4-week treatment period, efficacy diminished for both drugs. From these data, it cannot be determined whether the lack of rebound insomnia with zolpidem is a result of drug dose or some property of the drug such as receptor selectivity.

Adult↗
PubMed1997

Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders.

OBJECTIVE: Primary insomnia and insomnia related to mental disorders are the two most common DSM-IV insomnia diagnoses, but distinguishing between them is difficult in clinical practice. This analysis was performed to identify clinical factors used by sleep specialists to distinguish primary insomnia from insomnia related to mental disorders. METHOD: Clinicians evaluated 216 patients referred for insomnia at five clinical sites, rated a list of clinical factors judged to contribute to each patient's presentation, and assigned diagnoses. Analysis of variance was performed, with contributing factors as the dependent variable and diagnostic group and clinic location as independent variables. RESULTS: Sleep specialists rated a psychiatric disorder as a stronger factor for insomnia related to mental disorders and rated negative conditioning and sleep hygiene as stronger factors for primary insomnia. However, a psychiatric disorder was rated as a contributing factor for 77% of patients who received a first diagnosis of primary insomnia. CONCLUSIONS: While neither sleep hygiene nor negative conditioning is a diagnostic criterion in DSM-IV, these results support the face validity of these clinical factors distinguishing between primary insomnia and insomnia related to mental disorders. The use of a psychiatric disorder as an inclusion criterion for insomnia related to mental disorders and an exclusion criterion for primary insomnia reinforces a categorical distinction between the two diagnoses, but the contribution of psychiatric symptoms in primary insomnia appears to be a clinically relevant one. These findings suggest the need for studies on the validity of negative conditioning and sleep hygiene in the etiology of primary insomnia, as well as on the significance of psychiatric disorders, especially depression, in primary insomnia.

Adolescent↗
PubMed1997

The sleep/wake habits of patients diagnosed as having obstructive sleep apnea.

STUDY OBJECTIVE: To determine the sleep/wake habits of patients diagnosed as having obstructive sleep apnea (ie, respiratory event index [REI] > or = 5). DESIGN: Case series with prospective data collection to determine the relationship among sleepiness, REI, and sleep/wake habits. Patients were grouped according to their multiple sleep latency test (MSLT) results (< or = 5 and > 5) and REI (mild REI < or = 20; moderate REI > 20 but < or = 60; and severe REI > 60). SETTING: An American Sleep Disorders Association-accredited sleep laboratory. PATIENTS: Three hundred ninety (325 male, 65 female) consecutive patients seen between June 1993 and January 1995 for evaluation of sleep apnea. This included a sleep, medical, and psychiatric evaluation followed by a physical examination. Sleep histories and sleep/wake habits were recorded by a physician trained in sleep medicine. Polysomnographic evaluation consisted of a nocturnal clinical polysomnogram (CPSG) and an MSLT on the following day. Of 390 patients, 268 completed polysomnographic evaluation (CPSG and MSLT). MEASUREMENTS AND RESULTS: Sleepy (MSLT < or = 5) patients with mild (REI < or = 20) and moderate apnea (REI > 20 < or = 60) reported spending significantly less time in bed than sleepy patients with severe apnea (REI > 60). Those with severe apnea (REI > 60) reported napping significantly more and experienced a more severe disruption of their routine daily activities because of sleepiness when compared with mild and moderate OSA patients. CONCLUSIONS: These data suggest that sleep habits have an important modulatory effect on the level of sleepiness and this effect is lost as the severity of sleep-disordered breathing increases.

Aging↗
PubMed1997

Daytime sleepiness: an epidemiological study of young adults.

OBJECTIVES: Although excessive daytime sleepiness is associated with increased risks for accidents, decreased productivity, and interpersonal difficulties, information on its epidemiology is scarce. This paper examines correlates of and suspected risk factors for daytime sleepiness from a longitudinal epidemiological study of young adults. METHODS: The sample consisted of 1007 randomly selected young adults from a large health maintenance organization in southeast Michigan. Data were gathered in personal interviews conducted with 97% of the sample 5.5 years after baseline. Information on sleep characteristics in the last 2 weeks, including daytime sleepiness, nocturnal sleep onset, snoring, and hours of sleep, was collected on a self-administered instrument. Psychiatric disorders were measured by the National Institute of Mental Health's Diagnostic Interview Schedule. RESULTS: The average length of nocturnal sleep on weekdays was 6.7 hours. Daytime sleepiness was inversely related to hours of sleep and positively related to the ease of falling asleep at night; it varied significantly by employment and marital status. Snoring was associated with increased daytime sleepiness, as was recent major depression. CONCLUSIONS: Factors that might increase daytime sleepiness among young adults include social factors (being single and being employed full time) and pathological conditions (frequent snoring and major depression).

Adult↗
PubMed1997

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

We have selected a panel of human tumor xenografts for in vitro and in vivo studies that allows an indication of selectivity of action of novel chemotherapeutic agents. We report here the antitumor activity of the flavone flavopiridol (previously designated L86-8275), which has been selected for further studies based in part on its behavior in the anticancer drug screening system of the United States National Cancer Institute. Eighteen human tumor and five cell line-derived xenografts established by serial passage in nude mice in our laboratory were used as tumor models for in vitro investigations using a modified double-layer soft agar assay. In vivo investigations were completed in nude mice bearing advanced-stage s.c. growing prostate cancer xenografts. Antitumor activity in vitro (test/control </= 30%) of flavopiridol was observed at the very low concentration of 0.1 ng/ml in three of four prostatic xenografts and in one melanoma xenograft. Overall, in 14 of 23 (61%) tumor xenografts, drug treatment resulted in a IC70 of <10 ng/ml, demonstrating the high antiproliferative potential of flavopiridol. Toxicity to in vitro bone marrow cultures was evident only at 100 ng/ml, indicating potential high selectivity for susceptible tumor cells. Comparison of tumor cells with bone marrow samples tested showed clear prostate carcinoma and moderate melanoma selectivity. In vivo studies of flavopiridol confirmed antitumor activity in both prostate cancer xenografts investigated. At the maximal tolerated dose of 10 mg/kg/day administered p.o. on days 1-4 and 7-11, flavopiridol effected tumor regression in PRXF1337 and tumor stasis lasting for 4 weeks in PRXF1369. We conclude that flavopiridol shows strong prostate-and moderate melanoma-specific antitumor activity in vitro. The prostate antitumor activity is also reflected by the two in vivo models studied. Initial clinical efforts with flavopiridol might consider early evaluation in patients with prostate carcinoma.

Animals↗
PubMed1996

The reliability of the diagnostic features in patients with narcolepsy.

This study determined the test-retest reliability of the polysomnographic findings in narcolepsy. The diagnosis of narcolepsy was based on clinical symptoms and polysomnographic signs. Control subjects were screened before participation and were split based on their screening multiple sleep latency test (MSLT) into high- and low-MSLT groups. Subjects completed two polysomnographic evaluations with at least 5 days between laboratory tests. Narcoleptics had lower sleep efficiencies and high stage 1% when compared to the low MSLT control group. They had more awakenings and less stage 2% than the control groups. Narcoleptics had a shorter latency to 1 when compared to the high-MSLT group but comparable to that of the low-MSLT group. Narcoleptics had a higher number of sleep-onset rapid eye movement periods (SOREMPs) than both control groups. The MSLT scores were stable across the two evaluations and showed a statistically significant correlation. Twenty-eight of the 30 narcoleptic subjects had two or more SOREMPs on reevaluation. None of the controls had multiple SOREMPs. Thus, multiple SOREMPs were shown to be a reliable finding in patients with narcolepsy.

Adolescent↗
PubMed1996

Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.

In a longitudinal epidemiological study of young adults, we estimated the association between sleep disturbance and psychiatric disorders, cross-sectionally and prospectively. A random sample of 1200 was drawn from all 21-30-year-old members of a large health maintenance organization (HMO) in Michigan; 1007 were interviewed in 1989 and 979 were reinterviewed in 1992. Lifetime prevalence of insomnia alone was 16.6%, of hypersomnia alone, 8.2%, and of insomnia plus hypersomnia, 8%. The gender-adjusted relative risk for new onset of major depression during the follow-up period in persons with history of insomnia at baseline was 4.0 (95% confidence interval [CI] 2.2-7.0) and in persons with baseline history of hypersomnia, 2.9 (95% CI 1.5-5.6). When history of other prior depressive symptoms (e.g., psychomotor retardation or agitation, suicidal ideation) was controlled for, prior insomnia remained a significant predictor of subsequent major depression. Complaints of 2 weeks or more of insomnia nearly every night might be a useful marker of subsequent onset of major depression.

Adult↗
PubMed1996

Hypnotic self administration and dose escalation.

The dependence liability of benzodiazepines in the context of their use as hypnotics (i.e. by insomnia patients as pre-sleep medications) is unresolved. A recent study found that insomniacs self administer capsules at bedtime at a high rate, with triazolam (0.25 mg) taken as often as placebo. This study sought to determine if differential self administration would develop when multiple capsules are available nightly. Eighteen men and women, age 21-45 years, with insomnia complaints (nine with objective sleep disturbance and nine without) were studied, 1 week with placebo and 1 week with triazolam (0.25 mg). The two conditions were administered double-blind and presented in a counter-balanced order with a week between conditions. In each condition, after 3 consecutive sampling nights of the available single capsule for that condition, subjects could self administer 0-3 capsules before bed on the 4 subsequent nights. Triazolam was self administered as many nights as placebo, but the number of placebo capsules self administered was twice that of triazolam capsules. The objective insomniacs self administered more capsules than the subjective insomniacs and neither group differentially choose triazolam over placebo. The number of triazolam capsules taken nightly was stable and the number of placebo capsules variable. It is concluded that insomniacs show no short-term escalation of triazolam dose, but do choose an increased and variable number of placebos, a pattern which is interpreted as being insomnia relief-seeking behavior.

Adult↗
PubMed1996

Giant-cell tumour of the sphenoid bone: case report.

We report an 18-year-old woman with a giant cell tumour of the sphenoid bone. CT demonstrated a lytic soft-tissue mass arising from the sphenoid body, extending to the left petrous apex and into the nasopharynx. On MRI the tumour had nonspecific signal intensity, but there was contrast enhancement on both examinations. CT was better for showing the extent of the osseous disease, whereas MRI was more accurate as regards soft-tissue extension.

Adolescent↗
PubMed1996

Nocturnal sleep latencies among alert, alert-deprived and sleepy subjects.

Twenty-seven healthy, asymptomatic subjects participated in a study to determine repeated nocturnal sleep latencies as a function of level of daytime sleepiness. Subjects were screened polysomnographically and were determined to be free of any sleep pathology. Nine subjects had a screening multiple sleep latency test (MSLT) of < or = 5 min and 18 had a MSLT of > or = 10 min. Subjects were assigned to 3 groups, sleepy (MSLT < or = 5 min), alert, and alert sleep-deprived groups (MSLT > or = 10 min). Repeated nocturnal latencies to sleep were determined at 2300, 0110, 0310 and 0510 h on 2 nights with at least 5 days between nights. The results showed a main effect of group on the repeated nocturnal sleep latencies. Post-hoc tests demonstrated longer repeated nocturnal latencies among alert subjects compared to the sleepy and alert sleep-deprived subjects. The latter two groups had comparable sleep latencies. A significant main effect of time of night was also shown. The 0510 h latency was significantly shorter than the latencies at 2300 and 0110 h. The 0310 h latency was significantly shorter than the 0110 h latency and comparable to the 2300 and 0510 h latency. Significant correlations were found between daytime MSLT, repeated nocturnal sleep latencies, and nocturnal sleep time. These results show systematic differences in repeated nocturnal sleep latencies among sleep and alert subjects and extend the already described characteristics of these subjects by comparing them to a group of alert sleep-deprived subjects.

Adult↗
PubMed1996

Auditory awakening thresholds in sleepy and alert individuals.

Twenty-seven healthy men and women with regular sleep-wake habits (and no habitual napping) participated in a study to determine the relation between auditory awakening thresholds (AAT) and multiple sleep latency test (MSLT) scores. Subjects were free of any sleep complaints and were screened polysomnographically. Nine subjects had a screening MSLT of < or = 5 minutes (sleepy group), and 18 subjects had an MSLT of > or = 10 minutes. Subjects were assigned to three groups: a sleepy group, alert group and an alert sleep-deprived group. Subjects underwent 2 nights of AAT testing with at least 5 days in between each study night. AATs were determined at 0100, 0300, 0500 and 0730 hours. There were a total of 209 available AAT determinations, with a comparable number of trials across the groups. Because 68% of AAT determinations were done out of stage 2 non-rapid eye movement (NREM) sleep, the thrust of the analysis was based on the results of this stage of sleep. The AATs were averaged across the two experimental nights. Trials 1 and 2 (first half of the night) and 3 and 4 (second half of the night) were averaged for each subject. There was no main effect of group on AATs. However, there was a significant main effect of time and a significant group by time interaction. The former indicated an overall decline in AATs across the night. More importantly, the three groups had comparable AAT levels during the first half of the night:. Sleepy and alert-deprived subjects, however, failed to show a decline in AATs, whereas the alert group showed a significant decline in the second half of the night. This differential rate of decline in AATs is suggested to be related to the differences in sleep homeostasis among alert and sleepy individuals.

Acoustic Stimulation↗